Details

Autor(en) / Beteiligte

• Dongiovanni, Paola
• Donati, Benedetta
• Fares, Roberta
• Lombardi, Rosa
• Mancina, Rosellina Margherita
• Romeo, Stefano
• Valenti, Luca

Titel

PNPLA3 I148M polymorphism and progressive liver disease

Ist Teil von

• World journal of gastroenterology : WJG, 2013-11, Vol.19 (41), p.6969-6978

Ort / Verlag

United States: Baishideng Publishing Group Co., Limited

Erscheinungsjahr

2013

Quelle

MEDLINE

Beschreibungen/Notizen

• The 148 Isoleucine to Methionine protein variant (I148M) of patatin-like phospholipase domain-containing 3 (PNPLA3), a protein is expressed in the liver and is involved in lipid metabolism, has recently been identified as a major determinant of liver fat content. Several studies confirmed that the I148M variant predisposes towards the full spectrum of liver damage associated with fatty liver: from simple steatosis to steatohepatitis and progressive fibrosis. Furthermore, the I148M variant represents a major determinant of progression of alcohol related steatohepatitis to cirrhosis, and to influence fibrogenesis and related clinical outcomes in chronic hepatitis C virus hepatitis, and possibly chronic hepatitis B virus hepatitis, hereditary hemochromatosis and primary sclerosing cholangitis. All in all, studies suggest that the I148M polymorphism may represent a general modifier of fibrogenesis in liver diseases. Remarkably, the effect of the I148M variant on fibrosis was independent of that on hepatic steatosis and inflammation, suggesting that it may affect both the quantity and quality of hepatic lipids and the biology of non-parenchymal liver cells besides hepatocytes, directly promoting fibrogenesis. Therefore, PNPLA3 is a key player in liver disease progression. Assessment of the I148M polymorphism will possibly inform clinical practice in the future, whereas the determination of the effect of the 148M variant will reveal mechanisms involved in hepatic fibrogenesis.